June 12, 2019 / 5:27 AM / a month ago

BRIEF-Lysogene: 1st European Patient Treated In AAVance, Phase 2/3 Clinical Trial Investigating LYS-SAF302

June 12 (Reuters) - LYSOGENE SA:

* ANNOUNCED ON TUESDAY THAT FIRST EUROPEAN PATIENT HAS BEEN DOSED IN AAVANCE, A GLOBAL PHASE 2-3 CLINICAL TRIAL OF LYS-SAF302, GENE THERAPY FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IIIA (MPS IIIA)

* PHASE 2/3 TRIAL FIRST SET UP IN THE US AND TREATING PATIENTS SINCE FEBRUARY 2019

* EXPANSION OF TRIAL, TO EUROPE, TO ASSESS EFFICACY ON NEURODEVELOPMENTAL STATUS OF MPS IIIA PATIENTS

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below